| 1 |
Martinez CH, Mannino DM, Divo MJ. Defining COPD-related comorbidities, 2004-2014. J COPD Found 2014;1:51-63.
DOI
|
| 2 |
Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
DOI
ScienceOn
|
| 3 |
Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107:1376-1384.
DOI
ScienceOn
|
| 4 |
Sasaki T, Nakayama K, Yasuda H, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009;57:1453-1457.
DOI
ScienceOn
|
| 5 |
Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
DOI
ScienceOn
|
| 6 |
Kim J, Lee JH, Kim Y, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med 2013;13:51.
DOI
ScienceOn
|
| 7 |
Putcha N, Han MK, Martinez CH, et al. Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. J COPD Found 2014;1:105-114.
DOI
|
| 8 |
Kim SW, Lee JH, Sim YS, Ryu YJ, Chang JH. Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease. Korean J Intern Med 2014;29:466-473.
DOI
ScienceOn
|
| 9 |
Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140:626-633.
DOI
ScienceOn
|
| 10 |
Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010;19:127-133.
DOI
ScienceOn
|
| 11 |
Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J 2012;39:344-351.
DOI
|
webmaster
